ABT Abbott Laboratories

$ABT Rothschild & Co Redburn moved Abbott to Buy on Friday, lifting its target to 127 from 119 (per Benzinga, via MarketBeat). That is about 30 percent upside from Friday's close near 97.50. What stands out is how far the tape and the Street have drifted apart. The stock is down about 22 percent this year and still sits below its 50-day average. Meanwhile 21 analysts rate it a Buy, with an average target of 119.80. The validator is the Q3 print on Oct 21: consensus looks for adjusted EPS of 1.43 against 1.30 a year ago, and the company guides 5.45 to 5.60 for fiscal 2026. Tracking this into the Oct 21 print.

$ABT close above 20MA would be the first in weeks. The fact it didn't touch the gap below is bullish to me. Next two targets are in the chart.

$ABT love seeing us have a bounce back day back above $100+ like this - we have been needing it 🥂

$ABT Wow! Is it really a green day for us?!? I must be dreaming! 🥂 Many more to come as we grind our way back towards $130+. Have a great weekend all 😎

$ABT some day in the future, despite what will be the ongoing focus on the AI hype, companies with real earnings & solid cash flows will begin to matter to the market again. We will look back on ABT being under $100 as an absolute gift, & almost hard to believe. Until then, let's keep collecting the reliable dividend, just as ABT shareholders have since 1924, & for well over a hundred years now.

$ABT breaks the support of 98 and drifts lower towards ER, hope ER number will reverse the downwards trend

$ABT $IHI $XLV Abbott Laboratories (ABT) - Weekly Chart Improving momentum, with price so far holding that round psychological $100 trading number. Note: Earnings wildcard catalyst scheduled mid Oct.

$ABT | BULLISH 🐂 🏢 Business & Value: Premier healthcare & medical device titan! Q2 revenue surged +13.0% YoY to $12.59B ($1.31 EPS beat), prompting management to raise full-year EPS guidance to $5.45–$5.60! 🚨 Chart Setup: Textbook 1W macro trendline retest holding $96.00–$99.00 support! Smart money sweeping long-dated March 2027 $100C LEAPS ($214.6K) as price coils right on top of the primary volume shelf! 📈💥 🎯 Key Levels to Confirm: • Bull Trigger: Reclaim $102.50 ➡️ Targets: $107.50 / $112.50 / $123.78+ 🚀 • Bear Trigger: Hard break below $93.00 🛑 • Analyst Consensus: Strong Buy with $120.00–$130.00 price targets! Watching for the healthcare value bounce launch! 👀⚡ #ABT #stocks #hovdid

$ABT Dow turned green but this took a noose dive, making sense??! Has been very weak lately for some reason

$ABT they need to be doing some serious stock buy backs at these prices…. They did alittle last quarter but they really need to do more and get dilution from SJM deal back under control

$ABT Was expecting a lift from SimpleScreen CRC rollout that didn't happen, now has to wait for ER for next move

$ABT wow never seen a drop like this im so glad I got outright before the drop . $96 next stop . This will drop

$ABT QUICK all eyes and strong buys to PLUME to explode to 100$ Updated valuation! NICE!! THE TRAIN IS LEAVING!

$ABT lawsuit watch: an April suit alleges Abbott's FreeStyle Libre 2 showed normal readings while a diabetic patient's real blood sugar hit ~700 mg/dl, leading to ICU for DKA. Nothing to claim yet. Open Class Actions.

$ABT Guys ILs companies with solid working tech, with proven results are worth over $1.X billion, so off rip PDSB should be worth $11.50. If the NIH and IBRX is messing with them and the original tech pass MRK hands, $1.20 is cheap. Mastering how to handle and boost Interleukins to fight cancers are always game changers. See IBRX, SLS, IOVA, etc. You're welcome!

$ABT | Rothschild Redburn Upgrades Abbott Labs to Buy with $127 PT on Medical Devices Strength and Diagnostics Growth Rothschild Redburn stays bullish as Medical Devices momentum and Exact Sciences integration drive stronger growth outlook. 🔹 Follow for more analyst insights on other tickers.

$ABT oil prices went through the roof this weekend. I think this is finally the breaking point for consumer $SPY time to go defensive!

Abbott Laboratories reached a $385 million settlement with the U.S. Department of Justice, resolving False Claims Act allegations related to powdered infant formula produced at its Sturgis, Michigan, and Casa Grande, Arizona, facilities between 2018 and 2022. The agreement includes approximately $348.7 million for the federal government and $36.3 million for certain states over Medicaid-related claims. Importantly, Abbott admitted neither wrongdoing nor liability, which investors viewed as a clean resolution of a long-standing legal overhang. With the liability now quantified and largely settled, the stock gained despite a weak broader market, reaching an intraday high of $104.44 before stabilizing. The company-specific catalyst comes ahead of Abbott’s next earnings report, expected in mid-October. The broader S&P 500 fell 0.3%, the Dow 0.1% and the Nasdaq 0.3%, highlighting that ABT’s move was driven primarily by the settlement rather than sector or market strength. $ABT